| Literature DB >> 33134905 |
Lucia Cilloni1, Han Fu1, Juan F Vesga1, David Dowdy2, Carel Pretorius3, Sevim Ahmedov4, Sreenivas A Nair5, Andrei Mosneaga5, Enos Masini5, Suvanand Sahu5, Nimalan Arinaminpathy5.
Abstract
BACKGROUND: Routine services for tuberculosis (TB) are being disrupted by stringent lockdowns against the novel SARS-CoV-2 virus. We sought to estimate the potential long-term epidemiological impact of such disruptions on TB burden in high-burden countries, and how this negative impact could be mitigated.Entities:
Keywords: Covid-19; Epidemiology; Mathematical modellingabstract; Tuberculosis
Year: 2020 PMID: 33134905 PMCID: PMC7584493 DOI: 10.1016/j.eclinm.2020.100603
Source DB: PubMed Journal: EClinicalMedicine ISSN: 2589-5370
Expert consensus on potential disruptions arising from COVID-related lockdowns in three countries.
| Indicator | Reason for effect | India | Kenya | Ukraine |
|---|---|---|---|---|
| From initiation of lockdown | ||||
| Reduction in transmission (DS- and DR-TB) | Physical distancing | Drops by 50% | Drops by 50% | Drops by 50% |
| Initial (pre-care seeking) patient delay | Restriction on movements | Increase by 50% | Increase by 50% | Increase by 30% |
| Probability of diagnosis per attempted clinic visit | Reduced lab capacity and availability of healthcare staff | Drops by 70% | Drops by 70% | Drops by 50% |
| First-line treatment completion, public sector and any engaged private sector | Healthcare staff unable to monitor and support treatment as usual | Drops to 70%, from 90% | Drops to 70%, from 89% (HIV -ve) and 82% (HIV +ve) | Drops to 50%, from 74% |
| Second-line treatment completion, public sector and any engaged private sector | Drops to 25%, from 51% | Drops to 25%, from 72% | Drops to 25%, from 49% | |
| Starting one month into lockdown | ||||
| Proportion of TB diagnoses having DST result | Xpert machines and other lab facilities used for COVID-19 response | Drops to 5%from 30% | Drops to 5% from 46% | Drops to 25%, from 74% (new) and 47% (retreatment) |
| Treatment initiation | Stockouts and supply interruptions | Drops to 25% from 88% | Drops to 25% from 80% | Drops to 50%, from 93% |
| Proportion of PLHIV receiving IPT | Disruptions in HIV care | – | Drops to 10% | – |
Footnotes: Scenarios were constructed through a rapid consultation with experts in the Stop TB Partnership and USAID, the former using information from a rapid survey of national TB programmes 9. The scenarios listed here are not predictive, but illustrative on the basis of current information: they offer a basis for examining the potential impact of different types of disruption.
Footnotes:
Abbreviations: COVID-19: coronavirus disease 2019, DR: drug-resistant (i.e. rifampicin-resistant), DS: drug-susceptible, DST: drug susceptibility test, HIV: human immunodeficiency virus, IPT: isoniazid preventive therapy, PLHIV: people living with HIV, TB: tuberculosis.
For the initial levels and uncertainty intervals of these parameters in each country, see Tables S2–S5 (entries highlighted in yellow) in the supporting information.
Lockdowns would have the effect of reducing transmission in the community level, but also intensifying and prolonging exposure at the household level. As our models do not incorporate household vs community structure, these scenarios instead aim to capture the net effect of changes in household vs community transmission. In urban slums in particular, where TB transmission is strongest, overcrowding may tend to reduce the effect of any lockdown on community transmission. In section 3 in the supporting information, we present corresponding sensitivity analyses to these assumptions.
The initial patient delay is an assumed interval of active, infectious TB, prior to a patient's first presentation for care. It is calibrated to match epidemiological data (see Table S1 for data, and Tables S2–S5 for parameter estimates).
For simplicity, only the Kenya model incorporates the role of HIV/TB coinfection, which is estimated to account for 27% of incident TB. However, we note that Ukraine has a high burden of HIV as well; in the present study, our focus in Ukraine is on the role of drug-resistant TB.
Fig. 1The potential impact of a lockdown on TB incidence in India, Kenya and Ukraine. Shown is monthly TB incidence in each country, in 2020 and 2021, for two disruption scenarios: (i) a ‘mild’ scenario with a 2-month lockdown and a 2-month restoration (orange), and (ii) a ‘severe’ scenario with a 3-month lockdown and a 10-month restoration (red). Bars labelled with 'S' and 'R' denote, respectively, the suspension and restoration periods, with numbers giving the duration in months in each period. As described in the main text, we assume that the disruptions in Table 1 are in full effect during the suspension period, and that they are reduced to zero in a linear way over the restoration period. Shaded intervals show 95% Bayesian credible intervals, reflecting uncertainty in pre-lockdown model parameters. Cumulative excess TB incidence over the period 2020–2025 is given in Table 2.
Fig. 2The potential impact of a lockdown on TB deaths in India, Kenya and Ukraine. As for Fig. 1, but showing monthly TB deaths in each country. As in Fig. 1, bars labelled with 'S' and 'R' denote, respectively, the lockdown and restoration periods, with numbers giving the duration in months of each period. Shaded intervals show 95% Bayesian credible intervals, reflecting uncertainty in pre-lockdown model parameters. Excess TB deaths over the period 2020–2025 are listed in Table 2.
Excess TB incidence and deaths between 2020 and 2025 as a result of the different scenarios for COVID-related lockdowns.
| Country | Excess cases between 2020 and 2025 | Excess deaths between 2020 and 2025 | ||
| (% increase) [95% CrI] | (% increase) [95% CrI] | |||
| 2-month suspension + 2-month restoration | 3-month suspension + 10-month restoration | 2-month suspension + 2-month restoration | 3-month suspension + -month restoration | |
| India | 182,000 [159,000–211,000] | 1190,000 [1060,000–1330,000] | 83,600 [77,500–90,600] | 361,000 [333,000–394,000] |
| (1.43% [1.30–1.65%]) | (9.25% [8.53–10.40%]) | (3.65% [3.48–3.95%]) | (15.70% [15–16.80%]) | |
| Kenya | 489 [−2660–5720] | 24,700 [16,100–44,700] | 2460 [1590–3840] | 12,500 [8790–17,800] |
| (0.0076% [−0.35–0.81%]) | (3.36% [2.28–6.11%]) | (1.30% [0.86–2.30%]) | (6.58% [5.30–10.0%]) | |
| Ukraine | 835 [−460–1520] | 4350 [826–6540] | 332 [153–570] | 1340 [815–1980] |
| (0.60% [−0.30–1.03%]) | (2.96%[0.52–4.47%]) | (1.15% [0.55–1.73%]) | (4.64% [2.84–6.27%]) | |
Abreviations: CrI-credible interval. All estimates are over the period from the beginning (1 Jan) of 2020 to the beginning of 2025. Percentages show increases in cases and deaths relative to a baseline of no disruption (blue lines in Figs. 1,2).
Fig. 3Sensitivity analysis: influence of specific components of a lockdown on excess TB cases and deaths. Shown here is a ‘leave-one-out’ analysis, where we simulate a scenario with all disruptions in Table 1 in effect, with the exception of one (given by the label to the left). Bars in the figures show the excess TB burden between 2020 and 2025 arising from this scenario, relative to the scenario where all disruptions are in effect. Vertical lines mark median excess TB cases and deaths in the ‘full-impact’ scenario. The largest bars therefore indicate those types of disruption that are most influential, for excess TB burden. Left-hand panels show results in terms of excess TB incidence, and right-hand panels show excess TB deaths. Error bars show 95% credible intervals, calculated by iterating this process over 250 posterior samples for each country. Abbreviations: DST: drug susceptibility test, FL: first-line, HIV: human immunodeficiency virus, IPT: isoniazid preventive therapy, SL: second-line, Tx: treatment.
Fig. 4The role of undetected prevalent TB and the impact of short-term supplementary measures to reduce this burden. The left-hand panel shows, in the example of India, the growth in the prevalence of undetected and untreated TB during the lockdown period, taking the example of a 2-month lockdown followed by a 2-month restoration. As described in the text, this expanded pool of prevalent TB is a source of short-term increase in TB mortality, as well as seeding new infections of latent TB that manifest as incident TB disease over the subsequent months and years. The right-hand panel shows the effect of ‘supplementary measures’ that are instigated immediately upon lifting the lockdown, and that operate over a two-month period to reach these missed cases and initiate them on treatment as rapidly as possible. In practical terms, such efforts could be guided by notification targets. Shown in the figure is the example of a mild lockdown scenario, followed by supplementary measures that aim to reach a peak target of 14 (95%CrI 13–16) monthly notifications per 100,000 population.
Fig. 5Sensitivity analysis to the extent of TB transmission reduction during the suspension period. In other figures we assume that transmission is reduced by 10% (see Table 1), and here we examine the potential implications of more substantial reductions. Lines show the percent increase in cumulative incidence (upper row) and cumulative TB mortality (lower row) between 2020 and 2025, compared to a baseline of TB services continuing indefinitely at pre-lockdown levels. The horizontal dashed line in each figure indicates zero overall change; the region above this line corresponds to a net increase in TB burden over the next 5 years, and vice versa. Overall, and in agreement with recent analysis[22], the figure illustrates that TB transmission reductions are likely to lead to overall reductions in TB burden only when strong transmission reductions are combined with mild disruptions (orange lines, at >50% transmission reductions for Kenya, and >75% transmission reductions for India and Ukraine).